| scholarly article | Q13442814 |
| P2093 | author name string | Michael S Conte | |
| Anuran Chatterjee | |||
| Daisuke Akagi | |||
| Mian Chen | |||
| Robert Toy | |||
| P2860 | cites work | Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions | Q24648717 |
| Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals | Q24673096 | ||
| Atherosclerosis — An Inflammatory Disease | Q26776972 | ||
| Recent developments in CCR2 antagonists | Q28244881 | ||
| Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant | Q28252699 | ||
| Resolvin D1 and Its Precursor Docosahexaenoic Acid Promote Resolution of Adipose Tissue Inflammation by Eliciting Macrophage Polarization toward an M2-Like Phenotype | Q61575249 | ||
| Omega-3 fatty acids protect renal functions by increasing docosahexaenoic acid-derived metabolite levels in SHR.Cg-Lepr(cp)/NDmcr rats, a metabolic syndrome model. | Q64885170 | ||
| Remodeling of carotid artery is associated with increased expression of matrix metalloproteinases in mouse blood flow cessation model | Q73265468 | ||
| Remodeling with neointima formation in the mouse carotid artery after cessation of blood flow | Q73832982 | ||
| Remodeling and neointimal formation in the carotid artery of normal and P-selectin-deficient mice | Q73994984 | ||
| Human recombinant monocyte chemotactic protein and other C-C chemokines bind and induce directional migration of dendritic cells in vitro | Q28291482 | ||
| Maresin 1 mitigates LPS-induced acute lung injury in mice | Q28390696 | ||
| Macrophage biology in development, homeostasis and disease | Q29620350 | ||
| Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells | Q30462210 | ||
| Resolvin D2 restores neutrophil directionality and improves survival after burns | Q30539988 | ||
| Cutting edge: Parathyroid hormone facilitates macrophage efferocytosis in bone marrow via proresolving mediators resolvin D1 and resolvin D2. | Q30613107 | ||
| Pro-resolving lipid mediators are leads for resolution physiology | Q30829097 | ||
| Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis | Q33513370 | ||
| Macrophage proresolving mediator maresin 1 stimulates tissue regeneration and controls pain | Q34130101 | ||
| Aspirin-triggered lipoxin and resolvin E1 modulate vascular smooth muscle phenotype and correlate with peripheral atherosclerosis | Q34162546 | ||
| Omega-3 fatty acid-derived mediators 17(R)-hydroxy docosahexaenoic acid, aspirin-triggered resolvin D1 and resolvin D2 prevent experimental colitis in mice. | Q34197156 | ||
| Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis | Q34361910 | ||
| Effects of D-series resolvins on behavioral and neurochemical changes in a fibromyalgia-like model in mice. | Q34424812 | ||
| A novel anti-inflammatory and pro-resolving role for resolvin D1 in acute cigarette smoke-induced lung inflammation | Q34618718 | ||
| Clinical correlates of red blood cell omega-3 fatty acid content in male veterans with peripheral arterial disease | Q34621812 | ||
| Specialized proresolving mediator targets for RvE1 and RvD1 in peripheral blood and mechanisms of resolution | Q35098090 | ||
| Resolvin D2 is a potent endogenous inhibitor for transient receptor potential subtype V1/A1, inflammatory pain, and spinal cord synaptic plasticity in mice: distinct roles of resolvin D1, D2, and E1. | Q35623911 | ||
| Testosterone regulates bone response to inflammation. | Q35910549 | ||
| MicroRNA-663 regulates human vascular smooth muscle cell phenotypic switch and vascular neointimal formation | Q35957299 | ||
| Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing | Q36376065 | ||
| D-series resolvin attenuates vascular smooth muscle cell activation and neointimal hyperplasia following vascular injury | Q36860274 | ||
| Atherosclerosis: evidence for impairment of resolution of vascular inflammation governed by specific lipid mediators | Q36879456 | ||
| C-reactive protein and vein graft disease: evidence for a direct effect on smooth muscle cell phenotype via modulation of PDGF receptor-beta | Q36893296 | ||
| Experimental Rat and Mouse Carotid Artery Surgery: Injury & Remodeling Studies. | Q36916621 | ||
| The novel 13S,14S-epoxy-maresin is converted by human macrophages to maresin 1 (MaR1), inhibits leukotriene A4 hydrolase (LTA4H), and shifts macrophage phenotype | Q36945083 | ||
| Resolvin D2 prevents secondary thrombosis and necrosis in a mouse burn wound model | Q37102819 | ||
| Partial carotid ligation is a model of acutely induced disturbed flow, leading to rapid endothelial dysfunction and atherosclerosis | Q37406316 | ||
| Growing impact of restenosis on the surgical treatment of peripheral arterial disease | Q37457724 | ||
| Cardioprotective function of cardiac macrophages | Q38199943 | ||
| Monocyte/macrophage suppression in CD11b diphtheria toxin receptor transgenic mice differentially affects atherogenesis and established plaques | Q42612056 | ||
| Maresin 1, a proresolving lipid mediator derived from omega-3 polyunsaturated fatty acids, exerts protective actions in murine models of colitis. | Q42709394 | ||
| Aspirin-triggered 15-epi-lipoxin A₄ signals through FPR2/ALX in vascular smooth muscle cells and protects against intimal hyperplasia after carotid ligation | Q43076924 | ||
| Macrophage depletion by clodronate-containing liposomes reduces neointimal formation after balloon injury in rats and rabbits | Q44082556 | ||
| Vascular oxidant stress enhances progression and angiogenesis of experimental atheroma | Q44743432 | ||
| Interleukin-18 and macrophage migration inhibitory factor are associated with increased carotid intima-media thickening. | Q53648758 | ||
| The Influence of Peripheral Arterial Disease on Outcomes | Q56944148 | ||
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Maresin 1 | Q60998631 |
| resolvin D2 | Q60998704 | ||
| P304 | page(s) | 2504-2513 | |
| P577 | publication date | 2015-03-16 | |
| P1433 | published in | FASEB Journal | Q520194 |
| P1476 | title | Systemic delivery of proresolving lipid mediators resolvin D2 and maresin 1 attenuates intimal hyperplasia in mice | |
| P478 | volume | 29 |
| Q43231086 | A novel path of improving heart function after infarction |
| Q36330155 | Aspirin-triggered resolvin D1 attenuates PDGF-induced vascular smooth muscle cell migration via the cyclic adenosine monophosphate/protein kinase A (cAMP/PKA) pathway |
| Q93012793 | Atherothrombosis and the NLRP3 inflammasome - endogenous mechanisms of inhibition |
| Q46509154 | Biosynthesis of proresolving lipid mediators by vascular cells and tissues |
| Q30275955 | D-series resolvins inhibit murine abdominal aortic aneurysm formation and increase M2 macrophage polarization |
| Q58801536 | Dynamic Macrophages: Understanding Mechanisms of Activation as Guide to Therapy for Atherosclerotic Vascular Disease |
| Q92209481 | Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities |
| Q59328896 | Lipoxin and Resolvin Receptors Transducing the Resolution of Inflammation in Cardiovascular Disease |
| Q50197299 | Maresin 1 Maintains the Permeability of Lung Epithelial Cells In Vitro and In Vivo |
| Q29248094 | Maresin 1 induces a novel pro-resolving phenotype in human platelets |
| Q42835940 | Maresin 1 inhibits transforming growth factor-β1-induced proliferation, migration and differentiation in human lung fibroblasts |
| Q52576158 | Maresins: Specialized Proresolving Lipid Mediators and Their Potential Role in Inflammatory-Related Diseases. |
| Q60046269 | Microbiota control acute arterial inflammation and neointimal hyperplasia development after arterial injury |
| Q52681249 | New maresin conjugates in tissue regeneration pathway counters leukotriene D4-stimulated vascular responses. |
| Q59792010 | Opposing Effects on Vascular Smooth Muscle Cell Proliferation and Macrophage-induced Inflammation Reveal a Protective Role for the Proresolving Lipid Mediator Receptor ChemR23 in Intimal Hyperplasia |
| Q52369219 | Paradigm shift - Metabolic transformation of docosahexaenoic and eicosapentaenoic acids to bioactives exemplify the promise of fatty acid drug discovery. |
| Q64894558 | Perivascular delivery of resolvin D1 inhibits neointimal hyperplasia in a rabbit vein graft model. |
| Q39872912 | Perivascular delivery of resolvin D1 inhibits neointimal hyperplasia in a rat model of arterial injury |
| Q90735171 | Pro-resolving lipid mediators in the resolution of neointimal hyperplasia pathogenesis in atherosclerotic diseases |
| Q91973416 | Proresolving Lipid Mediators: Endogenous Modulators of Oxidative Stress |
| Q90341452 | Relationship Between Specialized Pro-resolving Mediators and Inflammatory Markers in Chronic Cardiac Disorders |
| Q37603197 | Resolution of Acute Inflammation and the Role of Resolvins in Immunity, Thrombosis, and Vascular Biology |
| Q45064553 | Resolution of vascular injury: Specialized lipid mediators and their evolving therapeutic implications |
| Q93333502 | Resolvin D1 decreases abdominal aortic aneurysm formation by inhibiting NETosis in a mouse model |
| Q29248096 | Resolvin D1, resolvin D2 and maresin 1 activate the GSK3β anti-inflammatory axis in TLR4-engaged human monocytes |
| Q34536887 | Resolvin D2 Enhances Postischemic Revascularization While Resolving Inflammation |
| Q39046533 | Resolving inflammation by using nutrition therapy: roles for specialized proresolving mediators |
| Q64902212 | Roles of Specialized Pro-Resolving Lipid Mediators in Cerebral Ischemia Reperfusion Injury. |
| Q90341456 | Specialized Pro-resolving Mediators Directs Cardiac Healing and Repair with Activation of Inflammation and Resolution Program in Heart Failure |
| Q39160278 | Specialized pro-resolving mediators in cardiovascular diseases |
| Q34523903 | Specialized proresolving lipid mediators in patients with coronary artery disease and their potential for clot remodeling |
| Q97420826 | The Role of Endogenous Eicosapentaenoic Acid and Docosahexaenoic Acid-Derived Resolvins in Systemic Sclerosis |
| Q39504951 | Unidirectional and sustained delivery of the proresolving lipid mediator resolvin D1 from a biodegradable thin film device |
Search more.